New Peer‑Reviewed Study Reveals Actionable Immune–Microenvironment Target in Brain Metastasis; Medicinova Advances Clinical Translation
View original at globenewswire.comNew Peer‑Reviewed Study Reveals Actionable Immune–Microenvironment Target in Brain Metastasis; Medicinova Advances Clinical Translation LA JOLLA, Calif., April 27, 2026 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ: MNOV) and the Standard Market of the Toky…
What we drew from this source
The claims Via News extracted from this document. We point to the source; we don't replace it.
Brain metastasis represents one of the most urgent and challenging frontiers in oncology.
60% confidenceSecreted MIF is a candidate liquid biopsy biomarker detectable in cerebrospinal fluid, supporting a translational, biomarker-guided clinical strategy.
60% confidenceThe publication of this work in Cancer Research provides strong mechanistic and translational rationale to pursue biomarker-driven clinical strategies for brain metastasis.
60% confidenceFocusing on brain-specific immune-microenvironment interactions rather than tumor-intrinsic alterations alone opens a new therapeutic avenue applicable across multiple primary tumor types.
60% confidenceMediciNova holds granted patents covering MN-166 for preventing and minimizing cancer metastasis across multiple solid tumor types, including pancreatic, lung, breast, colorectal and ovarian cancers, as well as melanoma.
60% confidenceIbudilast can effectively block MIF-CD74 signaling, reverse pro-metastatic immune reprogramming, and suppress brain metastasis growth in preclinical systems.
60% confidenceBrain metastases develop in up to 30% of patients with advanced solid tumors, most commonly arising from lung cancer, breast cancer, melanoma, and colorectal cancer, and remain an area of substantial unmet medical need.
60% confidenceMediciNova has a strong track record of securing investigator-sponsored clinical trials funded through government grants.
60% confidenceMN-166 (ibudilast) is currently in Phase 3 for ALS and DCM, is Phase 3-ready for progressive MS, and is being evaluated in Phase 2 trials for Long COVID and substance dependence.
60% confidenceTumor-derived MIF alters the functional state of microglia and infiltrating macrophages in the brain, converting them from a potentially protective role into a pro-metastatic one; inhibition of the MIF-CD74 signaling axis significantly reduced metastatic progression in multiple experimental models and fresh patient-derived brain metastasis samples.
60% confidencePatients with brain metastases have historically been excluded from many clinical trials, limiting progress in the development of targeted treatments.
60% confidenceMN-001 (tipelukast) was evaluated in a Phase 2 trial for IPF and a second Phase 2 trial in NAFLD is ongoing.
60% confidence